FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123708935> ?p ?o ?g. }

• W2123708935 endingPage "1471" @default.
• W2123708935 startingPage "1466" @default.
• W2123708935 abstract "Large randomized controlled trials have shown significant decreases in morbidity and mortality in leukaemia patients with posaconazole prophylaxis. However, the value of prophylaxis has been questioned in centres with a low incidence of invasive fungal diseases (IFDs) and pre-emptive treatment strategies. We prospectively evaluated the epidemiology of IFDs in acute myelogenous leukaemia (AML) patients undergoing first remission-induction chemotherapy before and after posaconazole prophylaxis had been introduced as a standard of care. Patients admitted from January 2003 to December 2005 received topical polyenes as antifungal prophylaxis (first group), while those admitted between January 2006 and December 2008 received 200 mg of oral posaconazole three times daily (second group). Other diagnostic and therapeutic standard operating procedures remained unchanged. A total of 82 patients in the polyene prophylaxis group and 77 in the posaconazole prophylaxis group were included in the final analysis. Baseline characteristics were well matched between groups. Patients receiving topical polyene prophylaxis were more likely to experience breakthrough IFDs (19.5% and 3.9%; P = 0.003) or breakthrough aspergillosis (13.4% and 2.6%; P = 0.018) than patients receiving systemic posaconazole prophylaxis. They also had more febrile days (mean 10.7 ± 9.66 and 7.3 ± 5.73; P = 0.007), longer need for inpatient treatment (mean 53.0 ± 24.16 and 46.0 ± 14.39; P = 0.026) and a shorter fungal-free survival (78.7 and 90.4 days; P = 0.024). No significant differences were observed for persistent fever, pneumonia, lung infiltrates indicative of invasive pulmonary aspergillosis, or attributable and overall mortality. After introduction of posaconazole prophylaxis for patients with AML, the number of febrile days, the incidence rate of IFDs and aspergillosis and the duration of hospitalization decreased significantly." @default.
• W2123708935 created "2016-06-24" @default.
• W2123708935 creator A5005202524 @default.
• W2123708935 creator A5011314849 @default.
• W2123708935 creator A5016885408 @default.
• W2123708935 creator A5031204955 @default.
• W2123708935 creator A5046329402 @default.
• W2123708935 creator A5053451287 @default.
• W2123708935 creator A5064623767 @default.
• W2123708935 creator A5070655188 @default.
• W2123708935 creator A5076077834 @default.
• W2123708935 creator A5087860754 @default.
• W2123708935 creator A5091508839 @default.
• W2123708935 date "2010-04-21" @default.
• W2123708935 modified "2023-10-07" @default.
• W2123708935 title "Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort" @default.
• W2123708935 cites W1968047266 @default.
• W2123708935 cites W1982439428 @default.
• W2123708935 cites W1984337414 @default.
• W2123708935 cites W1987006607 @default.
• W2123708935 cites W1988385266 @default.
• W2123708935 cites W1989345554 @default.
• W2123708935 cites W2007537399 @default.
• W2123708935 cites W2011862339 @default.
• W2123708935 cites W2055883059 @default.
• W2123708935 cites W2075207728 @default.
• W2123708935 cites W2082695689 @default.
• W2123708935 cites W2083352990 @default.
• W2123708935 cites W2087266489 @default.
• W2123708935 cites W2109088397 @default.
• W2123708935 cites W2117730870 @default.
• W2123708935 cites W2120523595 @default.
• W2123708935 cites W2123134253 @default.
• W2123708935 cites W2133328722 @default.
• W2123708935 cites W2139678747 @default.
• W2123708935 cites W2141698097 @default.
• W2123708935 cites W2142707841 @default.
• W2123708935 cites W2145167395 @default.
• W2123708935 cites W2150824761 @default.
• W2123708935 cites W2151483063 @default.
• W2123708935 cites W4230924492 @default.
• W2123708935 doi "https://doi.org/10.1093/jac/dkq121" @default.
• W2123708935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20410061" @default.
• W2123708935 hasPublicationYear "2010" @default.
• W2123708935 type Work @default.
• W2123708935 sameAs 2123708935 @default.
• W2123708935 citedByCount "105" @default.
• W2123708935 countsByYear W21237089352012 @default.
• W2123708935 countsByYear W21237089352013 @default.
• W2123708935 countsByYear W21237089352014 @default.
• W2123708935 countsByYear W21237089352015 @default.
• W2123708935 countsByYear W21237089352016 @default.
• W2123708935 countsByYear W21237089352017 @default.
• W2123708935 countsByYear W21237089352018 @default.
• W2123708935 countsByYear W21237089352019 @default.
• W2123708935 countsByYear W21237089352020 @default.
• W2123708935 countsByYear W21237089352021 @default.
• W2123708935 countsByYear W21237089352022 @default.
• W2123708935 countsByYear W21237089352023 @default.
• W2123708935 crossrefType "journal-article" @default.
• W2123708935 hasAuthorship W2123708935A5005202524 @default.
• W2123708935 hasAuthorship W2123708935A5011314849 @default.
• W2123708935 hasAuthorship W2123708935A5016885408 @default.
• W2123708935 hasAuthorship W2123708935A5031204955 @default.
• W2123708935 hasAuthorship W2123708935A5046329402 @default.
• W2123708935 hasAuthorship W2123708935A5053451287 @default.
• W2123708935 hasAuthorship W2123708935A5064623767 @default.
• W2123708935 hasAuthorship W2123708935A5070655188 @default.
• W2123708935 hasAuthorship W2123708935A5076077834 @default.
• W2123708935 hasAuthorship W2123708935A5087860754 @default.
• W2123708935 hasAuthorship W2123708935A5091508839 @default.
• W2123708935 hasBestOaLocation W21237089351 @default.
• W2123708935 hasConcept C120665830 @default.
• W2123708935 hasConcept C121332964 @default.
• W2123708935 hasConcept C126322002 @default.
• W2123708935 hasConcept C141071460 @default.
• W2123708935 hasConcept C16005928 @default.
• W2123708935 hasConcept C203014093 @default.
• W2123708935 hasConcept C2776391196 @default.
• W2123708935 hasConcept C2778566413 @default.
• W2123708935 hasConcept C2778602436 @default.
• W2123708935 hasConcept C2779548794 @default.
• W2123708935 hasConcept C2779629538 @default.
• W2123708935 hasConcept C501593827 @default.
• W2123708935 hasConcept C535046627 @default.
• W2123708935 hasConcept C61511704 @default.
• W2123708935 hasConcept C71924100 @default.
• W2123708935 hasConcept C86803240 @default.
• W2123708935 hasConcept C89423630 @default.
• W2123708935 hasConceptScore W2123708935C120665830 @default.
• W2123708935 hasConceptScore W2123708935C121332964 @default.
• W2123708935 hasConceptScore W2123708935C126322002 @default.
• W2123708935 hasConceptScore W2123708935C141071460 @default.
• W2123708935 hasConceptScore W2123708935C16005928 @default.
• W2123708935 hasConceptScore W2123708935C203014093 @default.
• W2123708935 hasConceptScore W2123708935C2776391196 @default.
• W2123708935 hasConceptScore W2123708935C2778566413 @default.
• W2123708935 hasConceptScore W2123708935C2778602436 @default.

• next